Image: Mother And Daughter Talking

Qelbree and ADHD Frequently Asked Questions

Icon: Magnifying Glass

Find the answers to some common questions

Qelbree is a nonstimulant treatment for ADHD in children aged 6-17. It’s a once-a-day pill that has been proven to help reduce symptoms of ADHD.

In clinical trials, the most common side effects were sleepiness, not feeling hungry, feeling tired, nausea, vomiting, trouble sleeping, and irritability.

Learn more about safety 

Qelbree met the goal of 3 different clinical trials – a significant reduction in ADHD symptom scores in 6 weeks. For some patients, Qelbree reduced ADHD symptom scores as early as week 1*.

Learn more about results 

*In one study of children 6-11 years of age, ADHD symptom score reductions were statistically significant for 100 mg and 200 mg doses, beginning at week 1. In a second study of adolescents 12-17 years of age, ADHD symptom score reductions were statistically significant for 400 mg, beginning at week 2.

In clinical studies, Qelbree was proven to help reduce ADHD symptoms. Reducing the impact of those symptoms can help improve your child’s difficult behavior related to ADHD.

Learn more about Qelbree’s efficacy 

Children on Qelbree take a once-a-day capsule to treat their ADHD. The capsule can also be opened and its entire contents sprinkled on a teaspoonful of applesauce and all consumed within 2 hours. Capsules and their contents should not be cut, chewed, or crushed.

Learn more about dosing 

IMPORTANT SAFETY INFORMATION ABOUT QELBREE

INDICATION

QelbreeTM (viloxazine extended-release capsules) is a prescription medicine used to treat ADHD in children ages 6 to 17.

IMPORTANT SAFETY INFORMATION ABOUT QELBREE
Qelbree may increase suicidal thoughts and actions, especially within the first few months of treatment [read more] or when the dose is changed. Tell your child’s doctor if they have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your child’s moods, behaviors, thoughts and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

IMPORTANT SAFETY INFORMATION ABOUT QELBREE
Qelbree may increase suicidal thoughts and actions, especially within the first few months of treatment or when the dose is changed. [read more] Tell your child’s doctor if they have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your child’s moods, behaviors, thoughts and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

Your child should not take Qelbree if they:
Take a medicine for depression called monoamine oxidase inhibitor (MAOI), or stopped taking an MAOI in the last 14 days. Also, your child should avoid alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline.

Qelbree can increase blood pressure and heart rate. Your child’s doctor will monitor these vital signs.

Qelbree may cause manic episodes in patients with bipolar disorder. Tell your child’s doctor if they show any signs of mania.

Do not let your teen drive or operate heavy machinery until you know how Qelbree will affect them. Qelbree may cause your teen to feel sleepy or tired.

The most common side effects of Qelbree include sleepiness, not feeling hungry, feeling tired, nausea, vomiting, trouble sleeping, and irritability. These are not all the possible side effects of Qelbree.

You may report negative side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please see Medication Guide including Boxed Warning.

IMPORTANT SAFETY INFORMATION ABOUT QELBREE

INDICATION

QelbreeTM (viloxazine extended-release capsules) is a prescription medicine used to treat ADHD in children ages 6 to 17.

IMPORTANT SAFETY INFORMATION ABOUT QELBREE
Qelbree may increase suicidal thoughts and actions, especially within the first few months of treatment [read more] or when the dose is changed. Tell your child’s doctor if they have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your child’s moods, behaviors, thoughts and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

IMPORTANT SAFETY INFORMATION ABOUT QELBREE
Qelbree may increase suicidal thoughts and actions, especially within the first few months of treatment or when the dose is changed. [read more] Tell your child’s doctor if they have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your child’s moods, behaviors, thoughts and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

Your child should not take Qelbree if they:
Take a medicine for depression called monoamine oxidase inhibitor (MAOI), or stopped taking an MAOI in the last 14 days. Also, your child should avoid alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline.

Qelbree can increase blood pressure and heart rate. Your child’s doctor will monitor these vital signs.

Qelbree may cause manic episodes in patients with bipolar disorder. Tell your child’s doctor if they show any signs of mania.

Do not let your teen drive or operate heavy machinery until you know how Qelbree will affect them. Qelbree may cause your teen to feel sleepy or tired.

The most common side effects of Qelbree include sleepiness, not feeling hungry, feeling tired, nausea, vomiting, trouble sleeping, and irritability. These are not all the possible side effects of Qelbree.

You may report negative side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please see Medication Guide including Boxed Warning.